Investor Relations

Corporate Profile

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

Change

Volume

52 Week High

52 Week Low

Jan 27, 2021 2:48 AM EST

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Mirum Pharmaceuticals Honors Alagille Syndrome Awareness Day with Launch of Disease Awareness Campaign

January 24, 2021

- The national campaign seeks to emphasize the unbearable burden ALGS has on patients and their families. - Mirum underscores its commitment to continued understanding of the rare liver disease through research and support of ALGS community. FOSTER CITY, Calif. --(BUSINESS WIRE)--Jan.

Mirum Pharmaceuticals Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients With Primary Sclerosing Cholangitis

January 14, 2021

FOSTER CITY, Calif. --(BUSINESS WIRE)--Jan. 14, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the first patient has been enrolled in Mirum’s Phase 2b VISTAS study evaluating volixibat in adult patients with primary sclerosing cholangitis (PSC), an idiopathic chronic

Mirum Pharmaceuticals Provides Corporate Update

January 12, 2021

- Completion of maralixibat rolling NDA targeted for Q1 2021 - Expecting first-patient-in for volixibat studies in ICP and PSC, and maralixibat study in biliary atresia in Q1 2021 - Launching volixibat primary biliary cholangitis program in H2 2021 - European commercial leader hired in anticipation

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 8, 2021

FOSTER CITY, Calif. --(BUSINESS WIRE)--Jan. 8, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that on January 8, 2021 , the

Events

J.P. Morgan Annual Healthcare Conference

Jan 12, 2021 at 5:20 PM EST

Listen to webcast

H.C. Wainwright Virtual BIOCONNECT 2021 Conference

Jan 11, 2021

Inaugural (Virtual) Investor Day

Dec 9, 2020 from 11:00 AM to 1:30 PM EST

Click here to register

Investor Relations

Investor Relations

Corporate Profile

Header Menu